How much funding has Starna Therapeutics raised?

Starna Therapeutics has raised $106.1M in total funding, most recently a Series B round.

Who are Starna Therapeutics's investors?

Starna Therapeutics's investors include Source Code Capital, Tencent, LYFE Capital, Hillhouse Capital, LAV (Lilly Asia Ventures), Sherpa Healthcare Partners.

When was Starna Therapeutics founded?

Starna Therapeutics was founded in 2021.

Where is Starna Therapeutics headquartered?

Starna Therapeutics is headquartered in Suzhou, China.

What industry is Starna Therapeutics in?

Starna Therapeutics operates in Biotech.

How many employees does Starna Therapeutics have?

Starna Therapeutics has 11-50 employees.

Starna Therapeutics

Pioneering Extrahepatic RNA Delivery

Suzhou, China · Founded 2021 · $106.1M raised

Biotech

Headquarters: Suzhou
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: starnatx.com
Total Funding: $106.1M
Last Round: $40.0M Series BJan 2026
Rounds: 4

About

Starna Therapeutics is a Suzhou, China-based biotechnology company founded in August 2021, focused on pioneering extrahepatic RNA delivery technologies using proprietary lipid nanoparticle (LNP) platforms. The company's tissue-specific LNPs (tsLNPs) and cell-selective LNPs (csLNPs) overcome the conventional limitation of LNPs accumulating in the liver, enabling RNA medicines to reach non-hepatic tissues with precision. Starna's pipeline includes in vivo CAR-T programs for autoimmune diseases, RSV and GBM vaccine candidates, and has raised over RMB 300 million in Series B funding co-led by LYFE Capital, Hillhouse Capital, and Lilly Asia Ventures.

Summary

Starna Therapeutics is a Biotech company based in Suzhou, China, founded in 2021. It has raised $106.1M in total across 4 rounds, most recently a $40.0M Series B round in Jan 2026. Investors include Source Code Capital, Tencent and LYFE Capital.